KISS
SKIN INFLAMMATION
GOODBYE!

Validated preclinical stage

Fast psoriasis healing

Strong efficacy

Low doses

No side effects

DRUG CANDIDATE FOR THE TREATMENT OF PSORIASIS AND SKIN INFLAMMATIONS

PAT1657 IS A STRONG AND FAST TREATMENT FOR CHRONIC INFLAMMATION AND PSORIASIS

EFFICACY CHRONIC INFLAMMATION

Chronic inflammation was induced on Skh-1 mice by applying **TPA*** on their back skin for **7 days**. Skins were treated with PAT1657 on days 8, 11, and 14. Inflammation induction was carried on during treatments.



Strong reduction of the inflammation with 3 applications only

In-vitro reduction of inflammation mediators in cultivated NHEK keratinocytes after induction with PMA**



PAT1657 is more active than clobetasol at reducing IL-6, IL-8 and TNF-α

PSORIASIS

Psoriasis symptoms were induced on balb-c mice by applying **imiquimod** on their back skin for **7 days**. Skins were treated with clobetasol*** or PAT1657 at days 7, 8, 9, and 10. induction of psoriasis symptoms were carried on during treatments.



Equivalent effect as clobetasol to **cure psoriasis in 4 days**

FAST RECOVERY
Improvement of symptoms **after the first application** & **TOTAL RECOVERY** of inflammation symptoms

NO SIDE EFFECT NO SKIN THINNING



Histology of psoriatic mice treated with **PAT1657** show **healthy skin** and **no thinning**.

NO TOXICITY

No effects were observed on rats in an acute toxicity test at 2,000 mg/Kg (OECD402 procedure)

**TPA: 12-O-tetradecanoylphorbol-13-acetate. **PMA: inflaming agent - phorbol myristate acetate. ***clobetasol: strong efficacy corticosteroid. ****dexamethasone: market reference corticosteroid*

POWERFUL CYTOPROTECTION

In-vitro cultured keratinocytes were inflamed using PMA, and treated with PAT1657 or with dexamethasone****

While dexamethasone does not prevent cell death, **PAT1657 protects from cell damage** as culture is similar to healthy control.



PAT1657 INNOVATION IN BRIEF

- **Strong efficacy non-steroidic small molecule, in development at preclinical stage**
- Molecule of plant origin with **optimized chemical structure** improving its activity
- Internal production of this novel molecule at **industrial scale** in compliance with GMP and ISO 9001

PAT
Plant Advanced Technologies

Plant Advanced Technologies (PAT, France) is a plant biotechnology company producing **rare, new actives of plant origin** designed for pharmaceutical, cosmetic and agrochemical markets.

PAT has developed an innovative API (PAT1657, patented since 2016) at preclinical stage to treat skin pathologies related to inflammation. This product is now ready for Licensing.

Contact us to obtain our complete pharmacological file:

PAT
Plant Advanced Technologies

Jean-François Ginglinger, PhD
Global R&D Partnerships Manager
Pharmaceutical API Dev. Manager
(out-licensing)
Cell: 0033 (0)6 71 31 53 54
jfg@plantadvanced.com
www.plantadvanced.com

ALPAT LISTED ALTERNEXT

Alternext
FR0010785790 ALPAT

All our activities are ISO 9001 certified

Join us